InvestorsHub Logo
Followers 47
Posts 12012
Boards Moderated 0
Alias Born 09/12/2017

Re: SonicHaven6 post# 230537

Monday, 03/04/2024 5:02:43 PM

Monday, March 04, 2024 5:02:43 PM

Post# of 232330
Whatever mr. hankey, howdy ho...--- Dr. Lalezari told a reporter from the Albuquerque Journal that he is "excited" by a "glimmer of hope" that Cytolin(R) might fulfill a "desperate need" for a salvage drug to rescue patients who are infected with multidrug resistant species of HIV. In other reports, Dr. Lalezari stated, "Cytolin(R) is the first immune therapy I've seen that has produced a significant reduction in viral burden in preliminary clinical trials. Previous attempts to develop an immune therapy for HIV disease have failed in this regard, leaving the treating physician without an immune-based drug for treating HIV/AIDS. I became interested in this project because of its potential for making a new class of drugs available for those living with AIDS."
https://www.biospace.com/article/releases/cytodyn-selects-b-quest-clinical-research-b-for-next-trial-of-hiv-aids-immune-therapy-/

So sayeth the "extremely successful brilliant rock star of a physician/researcher"

"that would not waste his time or reputation on a loser."

Wheres Cytolin now?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News